	Application (4umb
	Filing Date
	First Named Inver
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit
(Not for additional and at of it 1.33)	Examiner Name

	Filing Date		09190309
			1998-11-12
			R. Schneidewend
	Art Unit		2421
	Examiner Name Jasor		P. Salce
	Attornou Docket Number		RC489041

						U.S.I	PATENTS			Remove	
Examiner Initial*	Cite No	F	Patent Number	Kind Code ¹	Issue D	Date	Name of Pate of cited Docu	entee or Applicant ment	Rele	s,Columns,Lines where vant Passages or Relev es Appear	
	1	e	6529526	B1	2003-03	3-04	Schneidewend	ı			
If you wis	h to ad	ld a	additional U.S. Pater	t citatio	n inform	ation pl	ease click the	Add button.		Add	
				U.S.P	ATENT	APPLIC	CATION PUBL	LICATIONS		Remove	
Examiner Initial*	Cite N	No	Publication Number	Kind Code ¹	Publication Name of Patentee or Applicar of cited Document			Pages,Columns,Lines where Relevant Passages or Relevar Figures Appear			
	1										
If you wis	h to ad	id a	additional U.S. Public	shed Ap	plication	citation	n information p	please click the Ad	d butto	on. Add	
					FOREIG	GN PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No		oreign Document umber ³	Country Code ²		Kind Code4	Publication Date	Name of Patente Applicant of cited		Pages,Columns,Lines where Relevant Passages or Relevant	Tn

Initial*	No	Number ³	Code ² i	Code ⁴	Date	Document Document	Passages or Relevant Figures Appear	10
	1	96/36172	wo		1996-11-14	GEMSTAR DEVELOPMENT CORPORATION		
If you wish	If you wish to add additional Foreign Patent Document citation information please click the Add button Add							
			MON DATE			OLUMENTO.	Domous	

If you wish to add additional Foreign Patent Document citation information please click the Add button Add							
NON-PATENT LITERATURE DOCUMENTS Remove							
Examiner (Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where publisher.	T5				

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09190309	
Filing Date		1998-11-12	
First Named Inventor Danie		R. Schneidewend	
Art Unit		2421	
Examiner Name Jasor		P. Saloe	
Attorney Docket Number		RCA89041	

1		

If you wish to add additional non-patent literature document citation information please click the Add button Add FXAMINER SIGNATURE

Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3), 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST, 16 if possible. 5 Applicant is to place a check mark here if English language translation is attached

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09190309	
Filing Date		1998-11-12	
First Named Inventor	Danie	R. Schneidewend	
Art Unit		2421	
Examiner Name Jason		P. Salce	
Attorney Docket Number		RCA89041	

CERTIFICATION STATEMENT

Please see 37	CFR '	1.97 and	1.98 to make th	e appropriate	selection(s	s):
---------------	-------	----------	-----------------	---------------	-------------	-----

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patient office in a counterpart foreign application, and, to the knowledge of the person signifie pile certification after making reasonable inquiry, no tend of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.59(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.57(c)(2).

- See attached certification statement.
- The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- A certification statement is not submitted herewith

Brian I Dorini

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Registration Number

43504

Signature	/Brian J. Dorini/	Date (YYYY-MM-DD)	2012-06-08

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. There will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Comments of the Comment of t

Name/Print

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicide to is coluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan KORice is to process andior examine your submission related to a patient application or patient. If you do not furnish the requested privacy is the principal purpose of which the information is used to patient. If you do not furnish the requested more private in the privacy of the privacy is a privacy of the privacy in the privacy of th

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subiect matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuant to 5 U.S.C. 552a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, cuting an inspection of records conducted by GSA is part of that apency's responsibility to recommend improvements in records management practices and programs, under authority of 4 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations abavit individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of
 the application presume to 58 U.S. C. 159 or issuance of a patient pursuant to 55 U.S. C. 151. Further, a record
 may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public fifthe record was filled in
 an application which became abandoned or in which the proceedings were terminated and which application is
 referenced by either a published application, one of public inspections or an issued patient.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.